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Abstract
Background: The identification of suitable patients is a common problem in clinical trials that is
especially evident in tertiary care hospitals.
Methods: We developed and analysed a workflow, which uses routine data captured during
patient care in a hospital information system (HIS), to identify potential trial subjects. Study nurses
or physicians are notified automatically by email and verify eligibility.
Results: As a case study we implemented the system for acute myeloid leukemia (AML) trials in
Münster. During a test period of 50 days 41 patients were identified by the system. 13 could be
included as new trial patients, 7 were already included during earlier visits. According to review of
paper records no AML trial patient was missed by the system. In addition, the hospital information
system further allowed to preselect patients for specific trials based on their disease status and
individual characteristics.
Conclusion: Routine HIS data can be used to support patient recruitment for clinical trials by
means of an automated notification workflow.
Background
Patient recruitment is crucial for the success of any clinical
trial. Complete identification of eligible patients ensures
both timely execution of the trial and avoids selection
bias. Recruitment is a common and relevant issue in clin-
ical trials. A recent analysis of more than 100 trials
showed that less than a third of the trials achieved their
original recruitment target and half were awarded an
extension [1].
Given the high patient turnover of modern hospitals in
conjunction with complex inclusion and exclusion crite-
ria of many simultaneous active trials, patient recruitment
can be a challenging task. For instance, the registry of the
national cancer institute contains more than 5000 active
clinical trials [2]. There are several systems to support
identification of a suitable clinical trial for a specific
patient [3,4]. However, these systems are usually not inte-
grated into regular patient care. The treating physicians are
often not aware about the possibility of a clinical trial in a
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specific situation. The wide range of available trials and
the heavy workload of physicians might limit the capacity
to identify trials that are relevant for the patient.
In this paper we present and analyse a workflow, which
uses routine data captured during patient care in a major
hospital information system (HIS), to identify possible
trial subjects. There are few reports of this strategy, mainly
in the outpatient setting [5-7]. The key differentiator of
our approach is to use coded diagnosis information,
which is available in the inpatient setting, to improve pre-
cision – and thereby acceptance – of electronic alerts. Rou-
tine HIS data does usually not contain all information
regarding inclusion and exclusion criteria. Therefore we
aim at an automated screening method. Study nurses or
physicians are notified if a patient would be suitable for
clinical trials. Eligibility is verified by using the resources
of the data management system. This approach avoids an
unnecessary burden of additional data gathering in
patients unlikely to be suitable for a specific trial. Figure 1
presents the overall workflow.
In the next sections we describe how this workflow can be
implemented within a standard hospital information sys-
tem and present preliminary data from a pilot study in our
hospital.
Methods
For each clinical trial a database query is generated using
the report generator of the HIS (ORBIS® from Agfa Health-
care) [8]. Depending on inclusion and exclusion criteria
of each trial and available HIS items, the query is designed
to provide high recall and precision. Typically, admission
diagnosis (primary as well as secondary diagnoses, coded
according to international classification of diseases),
patient age, patient gender and routine lab values can be
Overview of HIS-based patient recruitment Figure 1
Overview of HIS-based patient recruitment. An automated HIS report triggers email notification of study nurses and 
physicians, who verify patient eligibility for a specific clinical trial.Trials 2008, 9:2 http://www.trialsjournal.com/content/9/1/2
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employed in this query. Figure 2 presents a sample query
for a clinical trial on AML.
This query is executed regularly (for instance once per
day) and its output is compared to a table of previous
query results. If there are new potential trial subjects, an
email to the responsible study nurses and/or physicians is
generated. To address privacy regulations, this email does
not contain any patient name. Instead, it just states that
there are potential new patients for a certain trial (Figure
3).
This notification email requests to log on to the HIS,
where the authorized user can retrieve the report of poten-
tial trial patients (Figure 4). Access to HIS requires direct
involvement in the care for a specific patient. By full access
to the electronic patient record additional information
can be retrieved to verify eligibility. If the patient is eligi-
ble for the trial, a study physician contacts the patient to
obtain informed consent. By means of a custom HIS form
actual inclusion or exclusion can be documented for each
patient.
Given the large number of simultaneously active trials,
technical parameters for each trial are organized by a trial
management tool. It provides trial title, data query for
each trial, contact persons for email notification and refer-
ences.
The time to train users to use the system was tracked by
the investigator.
Results
Our HIS-based patient recruitment workflow was imple-
mented for ongoing Münster AML trials (publications
from completed Münster AML trials see [9,10]). All
patients with AML were screened for trial eligibility. Dur-
ing a test period of 50 days (starting May 2007) 41
patients were identified by the system. 13 could be
included as new trial patients, 7 were already included
during earlier visits. During these 50 days altogether 363
inpatients were admitted to the department of hematol-
ogy and oncology. Review of paper records showed that
no AML trial patient was missed by the system.
From a technical perspective, the system remained stable,
CPU load of reporting was small. According to comments
of study nurses, the notification system eased access to
potential patients and reduced the number of phone calls
and site visits to identify suitable patients. In addition, the
hospital information system further allowed to preselect
Sample database query Figure 2
Sample database query. Adult patients with AML are identified.
Screen shot of automatic notification email Figure 3
Screen shot of automatic notification email.Trials 2008, 9:2 http://www.trialsjournal.com/content/9/1/2
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patients for specific trials based on their disease status and
individual characteristics.
One session of user training (approximately 1 hour) for
study nurses and physicians was sufficient. Currently, the
system is rolled out for additional clinical trials in neurol-
ogy and dermatology.
Discussion
Clinical trials are characterized by highly specialized doc-
umentation needs, specifically tailored to the require-
ments of an individual trial. In the context of Good
Clinical Practice (GCP) [11] regulations, data monitoring
needs to be applied to achieve high data quality. It is nec-
essary to validate electronic documentation systems for
clinical trials. General hospital information systems are –
at least at present – not capable to address all documenta-
tion needs of clinical trials [12].
However, during the evolvement process of electronic
patient records more and more clinical information
becomes available in HIS. In some cases – for instance
laboratory values – electronic data becomes a primary
data source. Our approach utilises routine HIS data – cap-
AML trial report with patient list (in German) Figure 4
AML trial report with patient list (in German). It can be filtered by new cases ("neue Fälle"), included ("eingeschloss-
ene") and excluded ("ausgeschlossene") cases and sorted by case number ("Fallnummer"), patient, admission date ("Aufnahme") 
and location ("Aufenthaltsort"). For each patient case number, name, date of birth, date of admission and discharge as well as 
location are provided. For each case inclusion ("in Studie aufnehmen") or exclusion ("aus Liste entfernen") can be documented.Trials 2008, 9:2 http://www.trialsjournal.com/content/9/1/2
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tured for administrative and clinical purposes – as an
automated screening tool for patient recruitment. Even if
not all items needed for inclusion and exclusion are avail-
able in the routine HIS, basic information like diagnosis,
gender and age appear to be sufficient for an automated
screening tool.
There are some reports in the literature regarding HIS-
based support for patient recruitment. For instance, Embi
[5] describes a system for a diabetes mellitus trial in an
outpatient setting which resulted in a significant increase
of patient enrollment. Weiner [6] analysed a real-time
alerting system in the emergency department and
observed improved study investigator notification. Afrin
[7] reports mass screening of lab values for a lupus nephri-
tis trial, which also highlights the issue of alert precision:
7 Mio. lab values were screened, 70 potential patients
identified, only 3 were enrolled into the trial.
Many false positive alerts can be annoying for physicians
and impact user acceptance. In our case, 20 of 41 alerts
were related to trial patients and no AML trial patient was
missed. A test period of 50 days is certainly not long
enough for a valid assessment of improved recruitment,
therefore we plan to do this kind of analysis after about
one or two years of routine operation. However, it dem-
onstrates a relatively high precision of notifications. We
capitalised on a specific, coded diagnosis which is com-
monly entered into electronic systems after patient
encounter. This delayed documentation is acceptable for
inpatient alerts, but obviously limits real-time notifica-
tion in the outpatient setting.
From our perspective, integration into standard HIS is rel-
evant for several reasons: A direct link to the patient record
is provided which facilitates eligibility verification. Since
all diagnoses and suspected diagnoses are entered into the
system at the day of admission (inpatient or outpatient),
eligible patients can routinely be identified before start of
therapy. Also, redundant data entry is avoided, because
routine HIS data is re-used for trial purposes.
Data privacy regulations are covered by standard HIS
access controls and protocols, so there is no need for addi-
tional authentication systems. Clinical users are familiar
with the HIS which limits the need for additional training
activities. When informed consent is obtained, additional
orders can be placed in the HIS order-entry-system accord-
ing to each trial protocol.
From a technical perspective, our approach does not need
external systems and avoids firewall issues. On the other
hand, it requires vendor-specific technical configuration
for each trial at each hospital site and is therefore prima-
rily suited for clinical trials with few centers.
Conclusion
Routine HIS data can be used to support patient recruit-
ment for clinical trials by means of an automated notifica-
tion workflow.
Our workflow is not a replacement for electronic data cap-
ture (EDC) systems in clinical trials, it is targeted to sup-
port patient recruitment. True integration of clinical and
research documentation by connecting HIS and EDC sys-
tems still remains an ambitious, but important goal for
future systems.
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